<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260810282049/en/ImmunityBio-Appoints-Dr.-Jim-Yong-Kim-Former-World-Bank-President-and-Global-Health-Leader-as-Vice-Chairman/">ImmunityBio beruft Dr. Jim Yong Kim, ehemaligen Weltbankpräsidenten und globalen Gesundheitsführer, zum Vice Chairman</a>
    </div>

      <div class="me-0 me-md-5">
        CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), ein Immunotherapie-Unternehmen in der kommerziellen Phase, gab heute bekannt, dass Dr. Jim Yong Kim dem Unternehmen als Vice Chairman beigetreten ist. Dr. Kim wird in einem neu geschaffenen Office of the Executive Chairman tätig sein, wo er sich auf die Stärkung der internationalen und globalen Beziehungen des Unternehmens ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260804702957/en/ImmunityBio-Reports-Record-Q2%C2%A02026-Net-Product-Revenue-of-50.7%C2%A0Million-Up-92-Year-Over-Year-First-Half-Revenue-Up-121-to-94.8%C2%A0Million/">ImmunityBio meldet Rekord-Nettoerlöse aus Produktverkäufen im zweiten Quartal 2026 von $50,7 Millionen, plus 92 % gegenüber Vorjahr; Halbjahresumsatz steigt um 121 % auf $94,8 Millionen</a>
    </div>

      <div class="me-0 me-md-5">
        CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), ein Unternehmen der Biotechnologie im kommerziellen Stadium, gab heute die finanziellen und operativen Ergebnisse für das zweite Quartal zum 30. Juni 2026 bekannt. Die Nettoerlöse aus Produktverkäufen beliefen sich auf $50,7 Millionen, was einem Wachstum von 92 % gegenüber dem Vorjahr und einem sequenziellen Anstieg von 15 ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260729329364/en/ImmunityBio-Receives-United-Arab-Emirates-UAE-Marketing-Authorization-for-ANKTIVA%C2%AE-Across-BCG-Unresponsive-Non-Muscle-Invasive-Bladder-Cancer-for-CIS-and-Papillary-Disease-and-Metastatic-Non-Small-Cell-Lung-Cancer/">ImmunityBio erhält Marketingzulassung der Vereinigten Arabischen Emirate (VAE) für ANKTIVA® bei BCG‑nicht ansprechendem nicht‑muskelinvasivem Blasenkrebs für CIS und papilläre Erkrankung sowie bei metastasiertem nicht‑kleinzelligem Lungenkrebs</a>
    </div>

      <div class="me-0 me-md-5">
        CULVER CITY, Kalif. -- (BUSINESS WIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), ein vertikal integriertes Biotechnologieunternehmen in der kommerziellen Phase, gab heute bekannt, dass das Emirates Drug Establishment (EDE) der Vereinigten Arabischen Emirate (VAE) eine Marketingzulassung für ANKTIVA® (nogapendekin alfa inbakicept) für zwei Indikationen erteilt hat. Die Zulassung umfasst ANKTIVA 0,4 m...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260601924208/en/ImmunityBio-Presents-New-Clinical-and-Comparative-Data-Across-Lung-and-Bladder-Cancer-at-ASCO-2026/">ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026</a>
    </div>

      <div class="me-0 me-md-5">
        CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirec...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-may-26-2026-in-immunitybio-inc-lawsuit---ibrx-302779780.html">The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/25/3300667/32716/en/ImmunityBio-IBRX-Facing-Lawsuit-After-FDA-Flags-Misleading-Cancer-Claims-Shares-Plunge-21-2B-Market-Cap-Lost-HBSS.html">ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Sci...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ibrx-deadline-ibrx-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-immunitybio-inc-securities-fraud-lawsuit-first-filed-by-the-rosen-law-firm-302780312.html">IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the &quot;Class Period&quot;), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityB...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost----hbss-302780587.html">ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS</a>
    </div>

      <div class="me-0 me-md-5">
        IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th Deadline SAN FRANCISCO, May 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/ImmunityBio-Inc-US45256X1037/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>